Concepedia

Publication | Open Access

Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks

DOIFull Paper Access

31

Citations

16

References

2013

Year

Tanya Lushchyk, Sankha Amarakoon, José Martínez-Ciriano, L. Ingeborgh van den Born, G. S. Baarsma, Tom Missotten
Acta Ophthalmologica

Abstract

At 1 year, bevacizumab administered every 6 or 8 weeks was not inferior to therapy administered every 4 weeks.

References

YearCitations

Page 1